Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.

PloS one - 1 Jan 2011

de Yñigo-Mojado Laura, Martín-Ruíz Itziar, Sutherland James D

Abstract excerpt

Since RNA interference (RNAi) has the potential to discriminate between single nucleotide changes, there is growing interest in the use of RNAi as a promising therapeutical approach to target dominant disease-associated alleles. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HEK293 Cells
Share to Genes, Reporter
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Nucleic Acid Conformation

Share to Parkinson Disease

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 21712955
DOI: 10.1371/journal.pone.0021352
PMCID: PMC3119704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21712955-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.PMID 21712955Read ↗

Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease.Semantic proximity Read ↗

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.Semantic proximity Read ↗

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing <i>in vivo</i> in CNSSemantic proximity Read ↗

Allele-specific silencing of dominant disease genes.Semantic proximity Read ↗

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.Semantic proximity Read ↗

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.Semantic proximity Read ↗

R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.Semantic proximity Read ↗

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damageSemantic proximity Read ↗

Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.Semantic proximity Read ↗

Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.Semantic proximity Read ↗

New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease.Semantic proximity Read ↗

Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.